Septerna downgraded by Wells Fargo with a new price target
$SEPN
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2025 | $14.00 | Overweight → Equal Weight | Wells Fargo |
| 11/19/2024 | $38.00 | Overweight | Analyst |
| 11/19/2024 | Buy | TD Cowen | |
| 11/19/2024 | $43.00 | Overweight | Wells Fargo |
| 11/19/2024 | $50.00 | Overweight | Cantor Fitzgerald |
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results. "Our Native Comp
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development
Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism.
SC 13D - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
DEFA14A - Septerna, Inc. (0001984086) (Filer)
DEF 14A - Septerna, Inc. (0001984086) (Filer)
S-8 - Septerna, Inc. (0001984086) (Filer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00
Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00
TD Cowen initiated coverage of Septerna with a rating of Buy
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins